Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur Sells 5,209 Shares

Health Catalyst, Inc. (NASDAQ:HCAT) COO Daniel Lesueur sold 5,209 shares of the business’s stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $5.76, for a total value of $30,003.84. Following the completion of the transaction, the chief operating officer now owns 86,044 shares in the company, valued at $495,613.44. This trade represents a 5.71 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Daniel Lesueur also recently made the following trade(s):

• On Monday, January 6th, Daniel Lesueur sold 5,209 shares of Health Catalyst stock. The shares were sold at an average price of $7.51, for a total value of $39,119.59.

Health Catalyst Stock Performance

HCAT stock opened at $5.49 on Friday. Health Catalyst, Inc. has a 1 year low of $5.32 and a 1 year high of $10.31. The company has a quick ratio of 1.41, a current ratio of 1.41 and a debt-to-equity ratio of 0.32. The stock’s 50 day moving average price is $6.93 and its 200 day moving average price is $7.44.

Health Catalyst (NASDAQ:HCAT) last posted its earnings results on Wednesday, November 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.03). Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The company had revenue of $76.40 million during the quarter, compared to analysts’ expectations of $76.27 million. During the same period in the previous year, the company posted ($0.22) EPS. Health Catalyst’s quarterly revenue was up 3.5% compared to the same quarter last year. As a group, research analysts forecast that Health Catalyst, Inc. will post -0.33 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Wells Fargo & Company dropped their price target on Health Catalyst from $13.00 to $10.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 21st. Citigroup dropped their target price on Health Catalyst from $10.50 to $10.00 and set a “buy” rating on the stock in a research report on Friday, January 10th. Royal Bank of Canada lowered their price target on Health Catalyst from $9.00 to $7.00 and set a “sector perform” rating on the stock in a report on Wednesday, January 15th. Canaccord Genuity Group lowered their price target on Health Catalyst from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Tuesday, January 21st. Finally, Piper Sandler restated an “overweight” rating and issued a $12.00 price target (up previously from $11.00) on shares of Health Catalyst in a report on Tuesday, November 26th. Two investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $10.60.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Janney Montgomery Scott LLC purchased a new position in shares of Health Catalyst during the 3rd quarter worth $897,000. Fred Alger Management LLC acquired a new stake in shares of Health Catalyst during the 3rd quarter worth $6,858,000. Millrace Asset Group Inc. acquired a new stake in shares of Health Catalyst during the 3rd quarter worth $1,568,000. Point72 Asset Management L.P. increased its holdings in shares of Health Catalyst by 69.4% during the 3rd quarter. Point72 Asset Management L.P. now owns 516,934 shares of the company’s stock worth $4,208,000 after buying an additional 211,805 shares during the last quarter. Finally, Essex Investment Management Co. LLC acquired a new stake in shares of Health Catalyst during the 3rd quarter worth $2,012,000. Hedge funds and other institutional investors own 85.00% of the company’s stock.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.